Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

60.37 +0.39 (+0.65%)

Delayed Quote Updated: 3:59 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

38 39 Next >

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗

October 10, 2022

Via Benzinga

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗

October 03, 2022

Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.

Via Benzinga

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗

September 30, 2022

The major indexes fell, with the S&P 500 breaking below bear market lows.

Via Investor's Business Daily

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

FDA Approves Expanded Use Of Roche's Influenza Treatment ↗

August 12, 2022

Via Benzinga

Kiniksa Inks Global License Agreement With Roche For Vixarelimab ↗

August 03, 2022

Via Benzinga

This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗

September 28, 2022

Via Benzinga

2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗

September 28, 2022

Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.

Via Benzinga

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗

September 19, 2022

Via Benzinga

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗

September 19, 2022

Via Benzinga

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says ↗

September 13, 2022

Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati

Via Benzinga

A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know ↗

September 12, 2022

While July gave markets around the world a breather, August reestablished 2022’s choppy financial conditions.

Via Benzinga

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche

September 07, 2022

From Good Therapeutics

Via Business Wire

No More Free COVID-19 At-Home Tests, Federal Government Says ↗

August 29, 2022

CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au

Via Benzinga

Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗

August 25, 2022

Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).

Via Benzinga

Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million ↗

August 20, 2022

Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront).

Via Talk Markets

China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech ↗

August 18, 2022

Via Benzinga

Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer ↗

August 16, 2022

Via Benzinga

OTC Markets' Most Active Securities Sees A Shake-up In July ↗

August 16, 2022

July gave world markets a breather from 2022’s poor financial conditions.

Via Benzinga

FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

August 16, 2022

From Genentech

Via Business Wire

Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older

August 11, 2022

From Genentech

Via Business Wire

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern ↗

August 08, 2022

Via Benzinga

These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month ↗

August 05, 2022

The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share...

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field ↗

August 03, 2022

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.